- Home
- ZWS vs IONS Comparison
ZWS vs IONS Comparison
Compare ZWS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZWS
- IONS
- Stock Information
- Founded
- ZWS 1891
- IONS 1989
- Country
- ZWS United States
- IONS United States
- Employees
- ZWS N/A
- IONS N/A
- Industry
- ZWS Industrial Machinery/Components
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ZWS Industrials
- IONS Health Care
- Exchange
- ZWS Nasdaq
- IONS Nasdaq
- Market Cap
- ZWS 7.9B
- IONS 6.8B
- IPO Year
- ZWS 2012
- IONS 1991
- Fundamental
- Price
- ZWS $46.65
- IONS $70.73
- Analyst Decision
- ZWS Buy
- IONS Strong Buy
- Analyst Count
- ZWS 5
- IONS 20
- Target Price
- ZWS $43.00
- IONS $75.35
- AVG Volume (30 Days)
- ZWS 1.0M
- IONS 2.1M
- Earning Date
- ZWS 10-28-2025
- IONS 11-05-2025
- Dividend Yield
- ZWS 0.76%
- IONS N/A
- EPS Growth
- ZWS 30.58
- IONS N/A
- EPS
- ZWS 1.01
- IONS N/A
- Revenue
- ZWS $1,614,000,000.00
- IONS $944,050,000.00
- Revenue This Year
- ZWS $7.44
- IONS $24.01
- Revenue Next Year
- ZWS $4.10
- IONS $4.06
- P/E Ratio
- ZWS $47.06
- IONS N/A
- Revenue Growth
- ZWS 4.74
- IONS 16.05
- 52 Week Low
- ZWS $27.74
- IONS $23.95
- 52 Week High
- ZWS $48.42
- IONS $71.87
- Technical
- Relative Strength Index (RSI)
- ZWS 52.65
- IONS 80.34
- Support Level
- ZWS $46.40
- IONS $68.03
- Resistance Level
- ZWS $47.76
- IONS $71.87
- Average True Range (ATR)
- ZWS 0.77
- IONS 1.70
- MACD
- ZWS -0.11
- IONS 0.02
- Stochastic Oscillator
- ZWS 52.66
- IONS 88.68
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.